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Vascular complications of diabetes mellitus represent a major public health problem. Although many steps forward have been
made to define the causes and to find the best possible therapies, the problem remains crucial. In recent years, more and more
evidences have defined a link between microbiota and the initiation, promotion, and evolution of atherosclerotic disease, even in
the diabetic scenario. There is an urgency to develop the knowledge of modern medicine about the link between gut microbiota
and its host’s metabolic pathways, and it would be useful to understand and justify the interindividual diversity of clinical
disease presentation of diabetic vascular complication even if an optimization of pharmacological treatment has been made or in
the case of young patients where hypertension, dyslipidemia, and diabetes are not able to justify a very quick progress of
atherosclerotic process. The aim of the present review is to gather all the best available evidence in this regard and to define a
new role of the microbiota in this field, from biomarker to possible therapeutic target.
1. Type 2 Diabetes Mellitus: A Chronic Low-
Grade Inflammatory Disease
Type 2 diabetes mellitus (T2DM) represents a chronic meta-
bolic disease characterized by a relative insulin deficiency due
to pancreatic β-cell dysfunction and insulin resistance in
target organs, with consequent hyperglycemia. It has become
a global public health problem because of an endemic pro-
gression worldwide, also resulting from an increasing preva-
lence of obesity and sedentary lifestyle [1]. Indeed, T2DM is
considered as a chronic, low-grade inflammatory disease
determined by long-term immune system imbalance, meta-
bolic syndrome, and/or nutrient excess [2].
Emergent evidences support the implication of inflam-
matory processes with an abnormal production of cytokines
and activation of inflammatory signaling pathways in the
development of this metabolic disease [3–6]. In the early
1990s, Hotamisligil et al. described an increase of tumor
necrosis factor- (TNF-) α in adipose tissue and, con-
versely, an improved peripheral glucose uptake with the
neutralization of TNF-α in animal models of obesity and dia-
betes [7, 8]. This finding marked a new era in understanding
that a subclinical inflammatory process triggers both insulin
resistance and metabolic dysfunction, which precede T2DM.
Advances in this field have recognized components of both
innate and adaptive immune responses in regulating the
inflammatory process [9]. Even, Tsai et al. have hypothesized
that T2DM could be considered as an autoimmune disease
[10]. In addition, T2DM is clearly associated with macro-
and microvascular complications that are considered as the
expression of the inflammatory process [11]. In particular,
atherosclerosis is a complex process resulting from an
inflammatory response to injury with the interaction of
numerous cell types and formation of fatty streaks that could
progress to atheromatous plaques, plaque destabilization,
and plaque rupture [12]. Endothelial dysfunction is an early
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event of this process that determines the alteration of
vascular homeostasis, and it stimulates the production of
proinflammatory cytokines [12]. Chronic hyperglycemia
condition accelerates the progression of atherosclerosis
because of the overproduction of reactive oxygen species
(ROS) by the mitochondrial electron transport chain, the
formation of intracellular advanced glycation end products,
the activation of protein kinase C, and the increase of polyol
pathway flux [13]. Excess of ROS also increases the expres-
sion of inflammatory and adhesion factors, the formation
of oxidized low-density lipoprotein, and insulin resistance
by activating the ubiquitin pathway, inhibiting the activation
of AMP-protein kinase and adiponectin, and decreasing
endothelial nitric oxide synthase activity [12].
1.1. Lower Extremity Arterial Disease in Diabetic Patients.
Diabetes is associated with accelerated atherosclerotic disease
that affects arteries of the brain, heart, and lower extremities
[14]. Therefore, diabetic patients have a higher risk of stroke,
myocardial infarction, and limb amputation [15]. In particu-
lar, peripheral artery disease (PAD), defined as the athero-
sclerotic occlusive disease of the lower extremities, is one of
the most severe conditions in patients with T2DM. Nowa-
days, PAD represents a public health problem with a signifi-
cant impact on healthcare and high economic burden [12].
Over 200 million people are affected with lower extremity
artery disease worldwide [13], and its prevalence increases
with the prevalence of T2DM, one of the major risk factors
[16]. Furthermore, PAD has special features and poorer
prognosis in diabetic than in nondiabetic patients [17]. Clin-
ical onset is frequently characterized by critical limb ischemia
and gangrene, typical manifestations of advanced disease
stages, due to a poorly symptomatic progression of these
patients during the earlier stage of disease and to their
reduced pain perception related to the concomitant presence
of peripheral neuropathy [18]. As a consequence, patients
with diabetes are at higher risk of lower extremity amputa-
tion than those without diabetes [6, 19–21]. In addition,
diabetic patients with PAD, compared with diabetic patients
without PAD, have also a higher risk of cardiovascular dis-
ease [22–25]. Despite its severity, PAD is still the least studied
compared to other diabetic vascular complications [26].
2. The Microbiota: The Oldest Guest
The human organism owns several metabolic pathways to
counter the inflammatory process determined by the contin-
uous exposition to the external environment and pathogens
and to endogenous oxidative factors [27]. The infection
results as one of both local and systemic principal
inflammation-promoting factors [28]. In the latter case, the
role of a cross-mimicry process [28–31] and a systemic
bloodstream translocation from a local origin [30, 32–34]
has been demonstrated as initiating and promoting events
of the systemic inflammation burden far from the site of
the original colonization or infection [35].
Specifically, several studies have enhanced a clear correla-
tion between Helicobacter pylori and atherosclerosis, known
as the plaque inflammation process [28, 30, 31, 36]. In
addition, genetic fragments of human-colonizing microbes
(Helicobacter pylori and periodontal microbes) have been
found in carotid artery samples [28, 37, 38] of patients
affected by PAD, demonstrating an atherosclerotic plaque
colonization. Moreover, other bacteria or viruses have been
discovered colonizing the atherosclerotic plaques (e.g.,
Chryseomonas, Veillonella, Streptococcus, Cytomegalovirus,
human immunodeficiency virus,Mycobacteria, Porphyromo-
nas gingivalis, Aggregatibacter actinomycetemcomitans,
Tannerella forsythia, Fusobacterium nucleatum, and Strepto-
coccus mutans) [28, 39–49]. The examples of microorganisms
implied in the indirect [30, 40, 41, 50–63] and direct
activation of the immunological system determining the
plaque atherosclerotic burden are continuously increasing
[30, 64–67], confirming the real necessity to deeply under-
stand this topic and so compensate for the actual lack of
knowledge about the basic mechanism of the microbiota’s
role in atherosclerosis [68–71].
Recent studies support the predominant role of the
infection at the base of the inflammation load focusing on
the outcomes of the actual available therapeutic solutions in
lower-limb PAD, such as endovascular revascularization pro-
cedures and major vascular surgery. The influence of bacte-
rial activity has been demonstrated in several unfavorable
outcomes, such as the restenosis after arterial angioplasty
[41, 50, 71–77] or any major adverse cardiovascular event
(MACE) [30, 59, 78], which represent the first cause of exitus
of patients affected by lower-limb PAD [79]. An interesting
possible explanation has been proposed, defining the role of
the bacterial atherosclerotic plaque colonization as an addi-
tional promoting factor of inflammation burden, after the
angioplasty trauma-induced local inflammation [80–83].
The sum of the two stimuli determines the increased pro-
duction of cytokines, the endothelial dysfunction, the
induction of the foam cells, the proliferation and migra-
tion of the vascular smooth muscle cells (VSMCs), the
powered tendency of platelets to aggregate, and the proin-
flammatory behavior of the perivascular adipose tissue
(PVAT) [30, 40, 41, 51–58, 60, 62, 63, 84–86].
2.1. The Microbiome. Recent hypothesis supports a comple-
mentary role of microbiota as a constitutive component of
the human organism rather than an inevitable and casual
colonization from the environment around us. This comple-
mentarity has just been introduced and partially understood
by the increasing studies that try to highlight the micro-
biome, the collection of microbial genomes, and the plasticity
that completes our genomic feature [64]. The microbiome is
the genetic characterization of the entire microbiota in a spe-
cific tissue [87]. Its crosstalk with the immune system modu-
lates and regulates the immune response against the host
[88]. In particular, the gut microbiome plays a fundamental
role in this modulation for its location and microbiota. The
gut microbial community is composed mainly of phyla
Bacteroides, Firmicutes, Actinobacteria, Proteobacteria, and
Verrucomicrobia [89], in different proportions. Interindivid-
ual variation is determined by a difference in the microbiome
and also by environmental factors, such as lifestyle, diet, anti-
biotics, and drug use [90, 91]. This amount of genetic data
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has been playing an unexplored role in the modulation of our
metabolism pathways and in our pathologies, such as obesity
[64, 92, 93] and diabetes [64, 94–99]. In the latter case, a dif-
ferent geographic origin influences the gut microbiome
showing as similar metagenomes that could encode similar
functions presenting a differently marked microbe species
composition [64, 99]. The microbiome plasticity is directly
influenced by influencing factors of the host itself, such as
the intrapartum neonatal colonization through the vaginal
canal transit, or totally host-independent factors, such as
the change of diet from maternal milk to the introduction
of solid food, the level of hygiene to which everyone differ-
ently has been exposed since birth, and the use of antibiotic
therapy during lifetime [64, 100].
Although the microbiota becomes definitive and adult-
like in the host at around three years of age [64, 101], the
microbiome still changes through the epigenetic mechanisms
that are induced by endogenous and exogenous factors [64].
3. The Microbiota and Microbiome in Type 2
Diabetes Mellitus
Evidence in animal and human models supports the hypoth-
esis that obesity and T2DM are associated with a deep gut
dysbiosis. Overnutrition could represent one of the main
starting points to alter gut microbiota locally and to initiate
systemic inflammatory processes through the mucosal bar-
rier [102, 103]. Qin et al. performed the first metagenome-
wide association study in T2DM using stool samples from
Chinese patients with T2DM [98]. They found that T2DM
patients had only a moderate degree gut bacterial dysbiosis.
Functional annotation analyses, however, indicated a decline
in butyrate-producing Roseburia intestinalis and Faecalibac-
terium prausnitzii, which may be metabolically beneficial,
and an increase in several opportunistic pathogen levels.
Another metagenome-wide association study was performed
on T2DM and conducted in Europe on postmenopausal
female patients with normal, impaired, or diabetic glucose
regulation [99]. In this study, Karlsson et al. found that Rose-
buria intestinalis and Faecalibacterium prausnitzii were
highly discriminant for T2DM, in contrast to the Chinese
cohort. The authors suggest that the two studies were consid-
erably different, not only for the different sequencing tech-
niques used but also for ethnic and dietetic influences.
Moreover, a previous smaller study found that T2DM
patients showed higher levels of Lactobacillus species in com-
parison to nondiabetics [94], as showed by both Chinese and
European studies. In addition, Zhang et al. found that normal
subjects differed from patients with prediabetes with higher
levels of Faecalibacterium prausnitzii andHaemophilus para-
influenzae T3T1, whereas Verrucomicrobiaceae, Akkerman-
sia muciniphila, and Clostridiales sp. SS3/4 were less
abundant [104]. The last result differs from the findings of
Qin et al., which described a reduction of Akkermansia muci-
niphila in Chinese patients with diabetes. These results, how-
ever, suggest that patients with T2DM have evidence of gut
dysbiosis. The reasons for the discrepancies may be deter-
mined by various confounding factors, such as different
study populations, different sequencing techniques used,
and different diets and drugs used [105].
Recent studies suggest that short-chain fatty acids
(SCFAs), such as acetate, butyrate, and propionate, as well
as the end products of fermentation of dietary fibers by the
anaerobic intestinal microbiota, might constitute a link
between the microbiota and systemic inflammatory diseases.
In particular, butyrate seems to have a direct role in the
development of extrathymic anti-inflammatory regulatory
T cells [106]. Trompette et al. demonstrated that mice fed a
high-fiber diet have an altered microbiota and are protected
from allergic airway inflammation [107]. They showed that
propionate regulated allergic inflammation, bone marrow
hematopoiesis, and dendritic cell function. These findings
suggest that metabolites produced by the gut microbiota
influence hematopoiesis and immune responses in the lung.
Thus, these microbiota-derived products might be important
players in the generation of local and systemic immunity/in-
flammation. According to the studies mentioned before, the
alteration on the production of SCFAs, especially butyrate,
observed in T2DM patients, might have a key role in the
development of low-grade inflammation [105].
Another important role in the development of a meta-
bolic syndrome has been demonstrated for the pattern recog-
nition receptor such as the toll-like receptor 5 (TLR5), a
component of the innate immune system expressed in the
gut mucosa and one that helps defend against infection
[108]. TLR5-deficient mice exhibited hyperphagia and devel-
oped hyperlipidemia, hypertension, insulin resistance, and
obesity, as well as an altered microbiota. Interestingly, the
transfer of intestinal microbiota from TLR5-deficient mice
to germ-free mice led to metabolic syndrome. These data
support the crosstalk of gut microbiota with the innate
immune system and suggest that the alteration of this link
is critical in the development of the metabolic syndrome. In
addition, studies show that gut-derived endotoxin—lipopo-
lysaccharide (LPS)—might be involved in the chronic
inflammation observed in T2DM. Cani et al. described that
a high-fat diet (HFD) increased the LPS content of the gut
microbiota and resulted in metabolic endotoxemia [95].
They observed that subcutaneous infusions of LPS into mice
determined insulin resistance and obesity similar to that after
feeding an HFD. Gut dysbiosis might increase LPS produc-
tion by gram-negative bacteria and lead to metabolic endo-
toxemia and low-level inflammation that could contribute
to the development of insulin resistance and T2DM [12].
3.1. The Microbiota in Atherosclerosis. An evident promoting
role of microbes in a nonspecific inflammatory mechanism
has been observed supporting an active participation of
microbiota in systemic metabolic processes of the human
body. At the base of this “inflammasome,” there are several
processes, such as an overproduction of proatherogenic
mediators (C-reactive protein (CRP); interleukin 18 (IL18),
IL1β, and IL6; and TNF-α), a hyperstimulated expression
of adhesive molecules (vascular cell adhesion molecule 1
and intercellular adhesion molecule 1) [28, 30, 40, 41, 50,
85, 109], synthesis and release of growth factors and
PVAT-derived adipokines, production of ROS, hormones
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(corticosteroids and sex hormones), and free fatty acids,
and a cytokine-related direct influence on the autonomic
nervous system [28, 60, 62, 63]. The latter phenomenon
is known as the neuroendocrine-immunitary crosstalk,
which finally causes an homeostatic unbalance that initi-
ates and promotes hypertension, insulin resistance, diabe-
tes, altered levels of low-density lipoprotein- (LDL-)
cholesterol, plasma triglycerides, high-density lipoprotein-
(HDL-) cholesterol [28, 110–112], and a rise of oxidative
molecules that determine the LDL-cholesterol oxidation,
with a worsening of the atherosclerotic plaque instability
and progression [28, 113, 114].
Bacterial colonization/infection of the vascular wall may
contribute to the pathogenesis of atherosclerosis by the acti-
vation of a local, and eventually systemic, immunological
response [115]. This process may involve each of the vascular
wall layers (the intima, media, and adventitia) [28]. The main
effect of a possible infection on the intima layer is the induc-
tion of endothelial dysfunction with a resulting dysregulation
in vasomotor function, thrombotic complications, and initi-
ation and progression of atherosclerosis [28]. There are
several lines of evidence to suggest that bacterial infection
activates platelets by a stimulatory effect on von Willebrand
factor binding and factor VIII associated with a hyperfibrino-
genemia state [116, 117].
The infection of the media layer may affect VSMC func-
tion and connective tissues that participate in the regulation
of blood pressure, the vascular lumen, and the modulation
of shear stress [84]. The adventitia layer is composed of
adventitial compacta and adventitial fat, the aforementioned
PVAT [118]. PVAT has recently been defined as the widest
endocrine tissue that humans own [62]. It produces adipo-
kines, hormones (corticosteroids and sex hormones),
cytokines (TNF-α, IL6, and IL8), growth factors (visfatin,
platelet-derived growth factor-BB, and transforming growth
factor-β), and other substances such as ROS, nitric oxide
(NO), hydrogen sulfide (H2S), free fatty acids, and plasmino-
gen activator inhibitor type 1 [28]. These substances regulate
inflammation, vasoreactivity, and vascular VSMC growth,
proliferation, and migration in the adjacent layers of the
vasculature [84]. Bacterial infection may modify the PVAT
functions [28].
An increasing amount of study evidences the association
of periodontal bacteria, such as Porphyromonas gingivalis,
Tannerella forsythia, Prevotella intermedia, Aggregatibacter
actinomycetemcomitans, Treponema denticola, Prevotella
nigrescens, Fusobacterium nucleatum, Eikenella corrodens,
Parvimonas micra, and Campylobacter rectus, and cardiovas-
cular disease [33, 34, 119]. The study conducted by
Tapashetti et al. shows higher CRP plasma level and a greater
mean carotid intima-media thickness (c-IMT) value in
patients with chronic periodontitis than in patients with
healthy gums [119]. Kosaka et al. found that higher levels
of salivary inflammatory cytokines were associated with peri-
odontal disease. Among these, higher salivary IL6 and TNF-α
were positively associated with both periodontal disease and
intensity of carotid atherosclerosis [120]. In the case control
study conducted by Chen et al., periodontal bacteria was in
13 of the 25 (52%) atherosclerotic samples obtained from
patients with aortoiliac and/or femoropopliteal occlusive dis-
ease [121]. These results confirm that periodontitis increased
fivefold the risk of having PAD and was associated with
increased serum IL6 and TNF-α concentrations.
New evidences of the importance of microbiota are con-
tinuously found in the multifaceted human metabolic net-
work as the proven reduction of the prevalence of
Eubacterium and Roseburia in gut microbiota of patients
who have already had an atherosclerotic symptomatic event,
with an opposite pattern of prevalence for Colinsella [28, 64].
Moreover, a different gut microbiota composition was found
in patients affected by diabetes [98] and atherosclerosis, giv-
ing the basis to hypothesize an atherosclerotic process
induced by a possible gut microbiota dysbiosis [28, 122].
The discovery of the increased dimension and lipid content
of the atherosclerotic plaques observed in mice fed with a
hyperlipid diet [111, 123] is an interesting example of lipid
trim imbalance mediated by the action of colonizing
microbes. Chen et al. have demonstrated that levels ofHelico-
bacter pylori immunoglobulin G (IgG) and serum IL18 were
significantly higher in subjects with increased c-IMT [85].
This evidence suggests a positive association between
Helicobacter pylori infection and subclinical carotid artery
atherosclerosis mediated by IL18. In addition, the coro-
nary atherosclerosis in patients affected by chronic heart
disease with an infection of Cag A-positive Helicobacter
pylori was explained by an infection related to the imbal-
ance between lipid metabolism and LDL-cholesterol oxi-
dation burden, the aggravation of which proved the
progression and instability of the atherosclerotic plaque
[28, 124]. The importance of this elegant crosstalk between
microbiota and the host metabolism is clearly enhanced by
a more aggressive disease phenotype observed in a specific
group of patients, according to their microbial composition.
Indeed, the presence of Chlamydia pneumoniae in blood
and plaques of these patients has been defined as a promoter
of hypercholesterolemia-induced atherosclerosis [111] that
could be a possible cause of restenosis after an angioplasty
procedure [28, 125, 126]. Another example of microbiotal
influence on prognosis could be the evidence of a raised
severity of stroke in Chlamydia pneumoniae seropositive
patients with an increased c-IMT [124, 127, 128].
Several data suggest that infections resulting from peri-
odontal or gut microbes have a direct influence on our endo-
crine system, on PVAT, and on pituitary-suprarenal action,
with a possible derived imbalance of the autonomic sympa-
thetic nervous system and metabolism homeostasis that
could induce hypertension, insulin peripheral resistance,
T2DM, increase of LDL-cholesterol and triglycerides,
decrease of HDL cholesterol associated to an even more oxi-
dative burden by ROS overproduction, and restenosis phe-
nomenon [28, 84]. Moreover, a leaky gut phenomenon that
allows a bloodstream translocation of bacterial fragments
and a direct atherosclerotic plaque colonization [28, 64]
could facilitate several processes, including neuroimmune
crosstalk [28, 40, 41, 51–56, 58], macrophage-specific reverse
cholesterol transport process modulation [28, 129–131], and
the development of many diseases, such as obesity and
T2DM [28, 64].
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In addition, it was observed that diabetic patients have
higher baseline plasma levels of LPS than the healthy control
group and a low prevalence of butyrate-producing bacteria
(e.g., Roseburia and Faecalibacterium spp.) known for anti-
inflammatory abilities [64, 98, 99].
The atherosclerotic plaque peroxidation is essential for
promoting LDL-cholesterol accumulation inside macro-
phage cells, which become foam cells. These cells promote
the upregulation of inflammasomes created by an overpro-
duction of cytokines [111, 132] and an overexpression of
adhesive molecules [111, 133]. Specifically, it has been docu-
mented that Porphyromonas gingivalis plays a main role in
the promotion of LDL oxidation and plaque instability and
rupture caused by metalloproteinase, as an initiating and
promoting factor of peroxidation [111]. Porphyromonas is
also involved in the progression of abdominal aortic aneu-
rism [28, 134] and in inducing endothelial activation or dys-
function through a state of systemic inflammation with
cytokines and metalloproteinase [111, 135–140]. In support
of this evidence, there is a suggestive experiment demonstrat-
ing the effect of Porphyromonas gingivalis injection in mice
fed with a hyperlipidic diet, where an increase of the athero-
sclerotic plaque thickness and of its lipid content has been
observed [111, 123]. Similarly, a hypercholesterolemia-
induced atherosclerotic process has been found following
the injection of Chlamydia pneumophila [111, 141].
Finally, obesity, a growing problem in modern society,
shares part of its pathogenesis and natural history with the
host-colonizing microbiota, finding several meeting points
with microbial metabolic influence. A characteristic Firmicu-
tes/Bacteroides ratio has been discovered in obese patients
with a surprising restoration of the normal proportion or
lean-like proportion, once patients experienced a loss of
weight [64, 92].
Several evidences are enlarging our knowledge and beliefs
about the unavoidable influence of microbiota and its metab-
olome on our metabolic system, and the comprehension of
this complex network is an absolute priority to introduce
new therapeutic means and preventive solutions to slow or
even stop the progression of atherosclerosis and its clinical
manifestations, such as the strongly disabling diseases like
the lower-limb PAD.
3.2. Restenosis after Percutaneous Angioplasty: The Possible
Role of Microbiota. Angioplasty proves to be one of the most
effective nonmedical treatments in diabetic PAD of the
lower limbs, with the erroneous belief of gaining the vessel
lumen enlargement in stented arteries rather than a simple
balloon-angioplasty procedure. A recent study has demon-
strated a loss in the lumen enlargement of the arteries
treated by endovascular revascularization stenting caused
by a neointimal hyperplasia that progressively reduces
the vessel lumen and determines a restenosis of the treated
vascular segment [80].
The effect of this hyperplastic phenomenon is the in-stent
restenosis, a local process caused by hypercellularity and a
low apoptosis rate [142].
This evidence deserves a notable scientific resonance
because, according to collected data, the gut-related systemic
inflammatory burden could be implicated in the neointimal
hyperplasia, with a possible involvement in the in-stent
microbe colonization as a further promoting factor [142].
In addition, different innate anatomic-functional charac-
teristics of the arterial samples obtained from different body
districts (e.g., the coronary artery and internal iliac artery)
have been observed, suggesting an emergent necessity for
new target-specific endovascular revascularization proce-
dures and major vascular surgery for the PAD-affected pop-
ulation, rather than a translation of nonmedical treatments
from the better-known coronary district to a totally different
scenario as PAD [72, 143, 144].
Finally, more and more bacteria, correlated to the
inflammation in the atherosclerotic process at the base of
the restenosis mechanism, are being found (e.g., Helicobacter
pylori, Chlamydia pneumophila). This evidence could
introduce new therapeutic solutions against the in-stent
restenosis, such as the addition of a microbe-specific antibi-
otic to the already used antiproliferation factors added to
stent devices (e.g., Rapamycin) [28, 76] or the adjacent extra-
vascular tissue antibiotic injection therapy with an expected
prevention of neointimal hyperplasia and consequently
in-stent restenosis [28, 71].
4. The Metabolome: From Waste to Biomarker
Since medical researchers have focused on the metabolic
products of human multisliced colonizing microbiota film,
a new interesting scenario has been proposed. The role of
metabolites in host inflammatory process modulation and,
consequentially, in atherosclerotic clinical manifestations as
PAD has been defined to be much more essential and incisive
than the producing microbe itself [145, 146].
An increasing number of studies enrich the knowledge
about the gut metabolome by studying tryptophan (trp),
kynurenine/tryptophan (kyn/trp) ratio, indole sulfonate, p-
cresyl sulfonate (PCS), hippuric acid (HA), indole-3-
carboxaldehyde (i3a), indole 3-proprionic (i3p), H2S, and
phenylacetylglutamine and their influence on atherosclerotic
phenomenon [147], like PAD in patients affected by a high
grade of severe atherosclerosis, an end-stage disease charac-
terized by an hemodynamic stenosis of carotid arteries aimed
at an endarterectomy, disabling claudication, or critical limb
ischemia undergoing an endovascular revascularization pro-
cedure or “demolitive” surgery with amputation in nonsolva-
ble PAD [145]. Specifically, the tryptophan depletion
determines an overactivation of the transduction signal of a
stress pathway [145, 148] and an elevated value of the kyn/trp
ratio is found in inflammatory statements, including infec-
tions with a proven positive relation to MACE. In addition,
a low value of the kyn/trp ratio has been observed in germ-
free mice with an interesting opposite tendency of this rela-
tion in case used for the first colonization of the same mice
[145, 149, 150]. Data about the gut microbes’metabolic prod-
ucts are continuously developing with several examples of
their effect on host homeostasis; for example, indole sulfo-
nate has been observed to have an active role in VSMC dys-
function, vessel calcification, and thickening of arteries
[145, 151]. It has been proven that PCS has a positive relation
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with cardiovascular death [145], while HA has an influencing
role on postvascular surgery cardiac events and also a par-
tially demonstrated positive correlation with ankle-brachial
index (ABI), an accepted approximation of the high grade
of atherosclerosis in PAD-affected patients [145].
In support of the demonstrative data showing the
growing role of gut microbe metabolites in initiating and
promoting the PAD process, a negative relation between
indole, trp, i3p, and i3a and a high grade of carotid stenosis,
disabling claudication, and critical limb ischemia (CLI) has
been defined [145]. Meanwhile, higher baseline plasma con-
centrations of 3-hydroxyanthranilic acid and higher kyn/trp
ratio have been traced in the advanced atherosclerosis group,
mostly accepted in populations affected by CLI undergoing
amputation of the lower limbs, clearly suggesting how a plas-
matic concentration of trp greatly reduces the predisposition
and risk of progression to an advanced phase of disease [145].
Similarly, increased levels of indole, i3p, i3a, and HA are
detectable in patients with a higher ABI index, while on the
other side, a negative correlation has been observed between
the ABI index and high levels of 3-hydroxyanthranilic acid
and high kyn/trp ratio [145].
Trimethylamine N-oxide (TMAO) deserves a particular
description and focus. Recently, it has been defined as an
independent risk factor for MACE [129, 152–157]. Tri-
methylamine (TMA) is a gut microbiota metabolite originat-
ing from the microbial metabolism of choline and found in
many kinds of food as free choline or as a part of several
compounds, such as betaine, L-carnitine derived from food
[152, 153], and ergothioneine found in mushrooms, beans,
and the liver and kidney of animals [152]. After the absorp-
tion from the gut lumen and once circulating in the blood-
stream, TMA reaches the host liver where hepatic flavin
monoxygenase produces TMAO [152]. The interest on this
metabolite is derived from the observed positive relation
between high levels of TMAO and markedly increased risk
of atherosclerosis [129, 152–154, 158, 159]. The plasmatic
levels of TMAO are influenced by diet with a higher plasma
concentration in the case of elevated-fat-content diet, west-
ern diet, and red meat consumption [152, 153, 160–168].
On the other hand, a lower determination has been detected
in patients affected by chronic kidney disease who respect a
low-protein diet [152, 169]. The glomerular filtration rate
acts like a determining factor of TMAO plasma concentra-
tion with an inverse proportion; therefore, there is an
increase of TMAO levels in the case of a reduction of renal
filtration ability and a restoration of healthy patient-like
levels after kidney transplant [152].
It has been demonstrated that many human gut-
colonizing bacteria are able to produce TMA increasing
the TMAO plasma concentration (Streptococcus sanguinis,
Desulfovibrio alaskensis, Desulfovibrio desulfuricans, Acine-
tobacter, Serratia, Escherichia coli, Citrobacter, Klebsiella
pneumoniae, Providencia, Shigella, Achiomobacter, Sporo-
sorcine that belongs to Firmicutes phylum, Actinobacteria
[152, 170]). In contrast, bacteria belonging to Bacteroidetes
are not capable of producing TMA [152, 166].
The characteristics of TMAO justify the importance of
improving our knowledge about this metabolite. In fact,
several responsibilities on creating an imbalance of host
homeostasis have been described, such as endothelial dys-
function, oxidative-stress status promotion, overexpression
of proinflammatory cytokines, and a positive relation with
elevated inflammation biomarkers, incidence of T2DM, and
chronic kidney disease [152].
In addition, TMAO appears essential for explaining part
of the lipid balance and the increase of scavenger receptors
(CD36 and scavenger receptor class A type 1 (SR-A1)),
contributing to the rise of fat accumulation inside foam cells,
a fundamental event of atherosclerotic plaque progress
[129, 152, 171]. Flavin-containing monooxygenase 3
(FMO3) has been declared the most active in converting
the liver enzyme of TMA in TMAO, and its activity is
positively related to higher plasmatic levels of TMAO.
FMO3 activation and the derived high levels of TMAO
are strictly linked to an alteration of reverse cholesterol trans-
port [152, 172], to facilitated hyperglycemia and hyperlipid-
emia (defined as increased levels of very-low-density
lipoprotein- (VLDL-) and LDL-cholesterol) [152, 159, 172],
to overexpression of TNF-α, IL6, CRP [162, 167], and insulin
resistance [152, 159], and finally to the promotion of athero-
sclerosis [129, 152–154, 158, 159]. Therefore, TMAO has
been demonstrated to be an independent influencing factor
of the imbalance between the host metabolism and the
inflammatory process. Moreover, it has been defined as
transmissible atherosclerosis susceptibility factor [160].
Further studies have been conducted to understand
clinical implications of TMAO. In fact, elevated plasmatic
levels of this metabolite have a predictive role for the of 5-
year all-cause mortality in stable patients affected by PAD
[161]. This evidence could result essentially in the establish-
ment of a new prognostic measurable blood marker to
improve the stratification assessment of patients by detecting
who deserves specific dietary supplementation or pharmaco-
logic therapy [152, 153, 173–175].
Moreover, TMAO has been seen to be a quite precise
predictive factor of the future risk of MACE and increased
incidence of stroke, myocardial infarction, and death
[129, 152–156, 160, 176–178]. This metabolite also has a
positive correlation with Syntax scores I and II (angio-
graphic grading tools to determine the complexity of cor-
onary artery disease, the high values of which are related
to cardiac mortality and MACE in patients undergoing
multivessel and, specifically, unprotected left main percuta-
neous coronary intervention) even after adjustments for
traditional risk factors [160].
5. Therapeutic Intervention
One of the first therapeutic proposals that have been sug-
gested for application in the clinical practice is oral tolerance
induction with self-antigens capable of reducing the inflam-
matory burden caused by the cross-mimicry phenomenon
[72, 179, 180]. Another interesting proposal, which is even
more successful, consists in dietary supplementation of
immune-modulator, anti-inflammatory, and antiangioge-
netic molecules containing food, such as catechin and
epigallocatechine-3-gallate found in green tea. Surprisingly,
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a decrease of Porphyromonas gingivalis-related cytokine pro-
duction in patients affected by periodontitis has been
unveiled, giving discrete hopes in new therapeutic options
to prevent and reduce the atherosclerotic process [181–185].
An additional possible new treatment could be fecal
transplantation or the fragmented intestinal microbiota
transplantation from lean healthy people that is described
to be a hopeful treatment that reduces the insulin resis-
tance and increases the butyrate producing microbiota
[64, 186].
Furthermore, given the data regarding TMAO, the new
therapeutic solutions could include a multifactorial reduction
of TMAO plasmatic levels, for example, through targeting
the gut microbiota TMAO producer [152] or the FMO3
enzymatic activity that reduces the conversion of TMA to
TMAO [152]. An alternative option could be a change of
dietary habits [152, 187], but it is not possible to reduce the
carnitine and choline intake according to their nutritional
importance [152]; therefore, it could be useful to encourage
the consumption of marine fish which is rich in cardiopro-
tective molecules such as ω3-polyunsaturated fatty acids
(eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA)) that are implicated in the amelioration of impaired
glycemic tolerance, in the reduction of adipose tissue-
induced inflammation, in the reduction of monocyte che-
moattractant protein-1 (MCP-1/CCL2), and in the increase
of IL10 [152, 165].
Other possible solutions are the introduction of new
effective prebiotics (all nondigestible food that stimulates
the growth of beneficial bacteria) [152, 188] and probiotics
(administrating specific bacterial strains such as Lactobacillus
paracasei) [152, 189]. The use of antibiotics aimed at elimi-
nating the TMAO producer microbes has also been proposed
[152, 155]. Further therapeutic options are represented by
the administration of an oral nonabsorbent binder to remove
TMAO or its precursors [35, 170]; the inhibition of TMA
precursors, for example, through 3,3-dimethyl-1-butanol
(DMB) (contained in balsamic vinegar, red wine, extra virgin
olive oil, and grape seed oil), that is an analogue of choline
that competes and inhibits choline-TMA-lyase [152, 190];
and the inhibition of enzymes involved in TMA biosynthesis
[152] using dietary supplements such as Gynostemma penta-
phyllum [168] (an herbal product used in China to treat
hyperlipidemia and obesity that is associated to a reduction
of TMAO levels) or Gancao (the root of Glycyrrhiza uralen-
sis) coadministered with a derivative of the Aconitum carni-
choelii root [191]. Finally, it has been shown that enalapril
is able to promote the renal excretion of TMAO [152, 175].
5.1. The Role of Antibiotics. The strong connection between
the hosting organism and the colonizing microbiota has
already been demonstrated and the scientific community
continuously tries to collect new evidences about this
crosstalk to find out new therapeutic ways and to manage
the outcomes of the natural history of the disease.
The urgent necessity to fight a life-limiting disease such
as PAD presents new challenges such as the achievement of
cardioprotective therapeutic solutions through available
sources. Nowadays, the use of available local modulators of
gut microbiota, such as antibiotics and probiotics, has been
demonstrated to be an effective protective factor for biologi-
cally different organs such as the cardiovascular system [192].
Mass spectrometry allows studying this revolutionary
administration of exogenous influencing factors of microbes
and the derived metabolome [192, 193] and permits compar-
ing the metabolic paradigm/pattern between the examined
case and the germ-free control [192, 194].
The oral administration of antibiotics and probiotics
becomes the key to fully understand the role of human
organism-colonizing microbes on our metabolic pathways.
In fact, a direct modulation of the gut microbiome composi-
tion could indirectly determine an evident cardiovascular
protective effect; on the other hand, the local injection of
the same antibiotics in the coronary arterial circulation is
associated to an ineffective cardioprotective outcome. In sup-
port of this evidence, during the trial of Lam et al., a group of
mice premedicated with vancomycin alone or a combination
of antibiotics (streptomycin, neomycin, bacitracin, and poly-
myxin B) showed a reduction of the necrotic myocardium
after the induced coronary ischemia, compared to the control
group treated with the same medication, directly injected in
the coronary arterial circulation. Surprisingly, the adminis-
tration of metabolites derived from phenylalanine, trypto-
phan, and tyrosine, at a sufficient concentration to
restore the pretreatment serum levels, provokes the loss
of the cardioprotective effect defined by the reduction of
the size of the necrotized tissue area [192]. Notably, the
used antibiotics are not absorbed and cannot reach the
bloodstream, confirming the totally indirect cardioprotec-
tive mechanism. The direct effect on the gut microbe com-
position results in a reduction of Clostridia and a rise of
Bacilli and Proteobacteria in the vancomycin-treated
group, while it presents a reduction of Bacilli and no effect
on Clostridia and Proteobacteria in the group treated with
the mixture of antibiotics [192]. This evidence generates a
new hypothesis: the cardioprotection mainly originates
from the modification of the metabolome derived from
the complex bacterial composition and interrelationship,
rather than a specific phylum. It is possible that the inter-
action between circulating metabolites and cell surface
receptors mutates the transduction signals of cellular sur-
vival pathways, leading to a worse cardiovascular outcome
than the examined treated group, or they can be implied
in the mitochondrial dysfunction worsening the evolution
of the adverse event [192, 195].
Encouraging data have been derived from the compre-
hension of possible implicated cell signaling pathways, such
as the Jak2 activity [192, 196]; the role of pyrazolopyrimidine
on the Src family protein kinases [192, 197, 198]; the TGFβ-
mediated response [192, 199]; the effect of the fungal
metabolite Wortmannin on mammalian target of rapamycin
(m-TOR), a member of phosphatidylinositol-4,5-bispho-
sphate 3-kinase (PI-3) kinase superfamily; and other cellular
transduction trails/paths worthy of further studies.
The established protective effect of orally administered
antibiotics on remote organs such as the cardiovascular
system demonstrated an effective reduction of the risk of
restenosis or narrowing of the vessel treated with angioplasty,
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stenting, or bypass with graft. The production of short-chain
fatty acids by the colonic bacteria fermentation of fibers taken
with diet influences the function of VSMCs, the principle
responsible for the vascular restenosis phenomenon [142].
The future will rely on a standardized antibiotic or probiotic
administration as a treatment and a protective factor against
the failure of the endovascular revascularization procedure
that actually remains the main therapeutic option in PAD
of the lower limbs.
Furthermore, the oral administration of vancomycin
affects the gut microbiota composition of the host, at the cost
of a minimal systemic absorbance, showing a relative
decrease of Gram-positive bacteria belonging to Firmicutes
phylum and the reduction of the plasmatic level of sodium
butyrate [142, 200, 201] and presenting an increase of the
Bacteroidetes/Firmicutes ratio and a rise of the Gram-
negative Proteobacteria [142]. The result is a relative decrease
of sodium butyrate Gram-positive producers, with a proof of
an expected major neointimal hyperplasia observed in the
vancomycin-treated group and an abolition of this same
effect if the plasmatic concentration of sodium butyrate
would have been restored by dietary supplementation,
although with the concomitant administration of vancomy-
cin. This confirms the antiproliferative and antimigratory
properties of sodium butyrate on VSMC [142].
5.2. Probiotics in Diabetic PAD. Probiotics could gain an
important role in the medical treatment of diabetic PAD.
The rationale behind their use is based on the effect of an oral
supplementation of microbes that shows a direct
modification of the gut microbiota composition, which could
be a further intervention against the dysbiosis found in this
kind of patients [68].
Probiotics are revealing a complemental action with the
antibiotic therapy in the selection of a protective combina-
tion of colonizing microbes. In fact, their systemic influence
appears effective in ameliorating the lipid profile imbalance
by reducing cholesterol plasmatic levels, increasing LDL-
lipoprotein resistance against the oxidation, and inducing a
decrease of the onset of insulin resistance in diabetic controls
[202–204].
The contemporary administration of ω3 fatty acids has
further empowered the effect of probiotics on host metabo-
lism with an excellent result on lipid control, insulin resis-
tance, and inflammatory response [202, 205–207].
Many alternatives have already been suggested as a possi-
ble probiotic therapy, in particular the probiotic VSL#3 (VSL
Pharmaceuticals Inc., Fort Lauderdale, FL) which is notably
interesting. It contains three strains of Bifidobacteria (B.
longum, B. infantis, and B. breve), four strains of Lactobacilli
(L. acidophilus, L. paracasei, L. delbruceckii subsp. bulgarius,
and L. plantarum), and one strain of Streptococcus salivaris
subsp. termophilus. The results observed during the use of
VSL#3 confirm the usefulness of its introduction in the phar-
macological therapy of PAD, with a further empowerment of
the beneficial effect obtained by the addition of ω3 fatty acids
as dietary supplementation. By the administration of probi-
otic VSL#3, interesting modulations on host metabolism
have been described, such as the modest reduction of IL1,
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Figure 1: The different components of the intestinal microbiota (left) are able to worsen atherosclerosis at the base of the diabetic PAD by
direct (top) and indirect (bottom) effectors.
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inflammatory atherosclerosis. Moreover, an increase of HDL
cholesterol levels; a decrease of triglycerides, LDL, and VLDL
lipoprotein levels; a decrease in fasting glycaemia and athero-
sclerotic index; and a marked modification of microbes in
stool samples have been also demonstrated [202].
An effective risk factor control is at the base of the med-
ical management of diabetic PAD, and the dietary supple-
mentation of probiotics could appear as a new means to
modify the natural history of this chronic, disabling, and
progressive disease. It is necessary, however, to discover
new combinations of supplementing microbes, focusing on
their beneficial properties on systemic metabolism. It also
important to respect the selection of the species contained
in the probiotics, because there are strains of microbes that
do not present an effective ability in the metabolic profile
modulation, such as Lactobacillus rhamnosus, Lactobacillus
fermentum, and Lactobacillus acidophilus, all of which have
been observed ineffective in the improvement of serum lipid
control [202, 208–210].
Moreover, the addition of prebiotics to the previously
described probiotic treatment presented further interesting
results, such as the reduction of plasmatic insulin with a
consequential amelioration of the insulin resistance, a reduc-
tion of total and LDL cholesterol levels, and a reduction of
triglycerides, accompanied by an elevation of HDL serum
levels. In addition, an improvement of the inflammatory
state has been described thanks to the decrease of CRP,
IL1β, and TNF-α plasmatic concentrations. Moreover, in
the symbiotic group, the one treated with probiotic and pre-
biotic supplementation, the count of Lactobacilli was higher,
and the count of Escherichia coli and fecal coliform was
lower [211].
A summary of the direct and indirect effectors involved
in the connection between intestinal microbiota and PAD is
reported in Figure 1.
6. Conclusions
In recent years, more and more evidences have documented
the relationship between intestinal microbiota and diabetic
PAD. The use of antibiotics is very frequent in patients
affected by T2DM and PAD, since they often suffer from
infected ulcers of the lower limbs. This could represent the
first type of intervention: the choice of antibiotic therapies
able to modulate, in one way or another, the intestinal micro-
biota represents an important objective. Furthermore, also
the use of prebiotics and probiotics, useful for modifying
the composition of the microbiota and the production of
harmful metabolites, represents a further field of study.
Finally, considering precision medicine, the study of a per-
sonalized therapy based on antibiotics, prebiotics, probiotics,
and targeted diet could provide a new therapeutic instrument
for the treatment of diabetic PAD.
Conflicts of Interest
The authors declare that they have no competing interests.
Authors’ Contributions
All authors have read the paper and agree that it can be
published.
References
[1] NCD Risk Factor Collaboration (NCD-RisC), “Worldwide
trends in diabetes since 1980: a pooled analysis of 751
population-based studies with 4·4 million participants,” The
Lancet, vol. 387, no. 10027, pp. 1513–1530, 2016.
[2] M. I. Schmidt, B. B. Duncan, A. R. Sharrett et al., “Markers of
inflammation and prediction of diabetes mellitus in adults
(Atherosclerosis Risk in Communities Study): a cohort
study,” The Lancet, vol. 353, no. 9165, pp. 1649–1652, 1999.
[3] B. B. Duncan, M. I. Schmidt, J. S. Pankow et al., “Low-grade
systemic inflammation and the development of type 2
diabetes: the Atherosclerosis Risk In Communities study,”
Diabetes, vol. 52, no. 7, pp. 1799–1805, 2003.
[4] F. Biscetti, G. Straface, C. F. Porreca et al., “Increased FGF23
serum level is associated with unstable carotid plaque in type
2 diabetic subjects with internal carotid stenosis,” Cardiovas-
cular Diabetology, vol. 14, no. 1, p. 139, 2015.
[5] F. Biscetti, G. Straface, G. Bertoletti et al., “Identification of a
potential proinflammatory genetic profile influencing carotid
plaque vulnerability,” Journal of Vascular Surgery, vol. 61,
no. 2, pp. 374–381, 2015.
[6] F. Biscetti, C. F. Porreca, F. Bertucci et al., “TNFRSF11B gene
polymorphisms increased risk of peripheral arterial occlusive
disease and critical limb ischemia in patients with type 2 dia-
betes,” Acta Diabetologica, vol. 51, no. 6, pp. 1025–1032,
2014.
[7] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman,
“Adipose expression of tumor necrosis factor-alpha: direct
role in obesity-linked insulin resistance,” Science, vol. 259,
no. 5091, pp. 87–91, 1993.
[8] C. Xia, X. Rao, and J. Zhong, “Role of T lymphocytes in type 2
diabetes and diabetes-associated inflammation,” Journal of
Diabetes Research, vol. 2017, Article ID 6494795, 6 pages,
2017.
[9] L. Khondkaryan, S. Margaryan, D. Poghosyan, and
G. Manukyan, “Impaired inflammatory response to LPS in
type 2 diabetes mellitus,” International Journal of Inflamma-
tion, vol. 2018, Article ID 2157434, 6 pages, 2018.
[10] S. Tsai, X. Clemente-Casares, X. S. Revelo, S. Winer, and
D. A. Winer, “Are obesity-related insulin resistance and type
2 diabetes autoimmune diseases?,” Diabetes, vol. 64, no. 6,
pp. 1886–1897, 2015.
[11] V. Guarner and M. E. Rubio-Ruiz, “Low-grade systemic
inflammation connects aging, metabolic syndrome and
cardiovascular disease,” Interdisciplinary Topics in Gerontol-
ogy, vol. 40, pp. 99–106, 2015.
[12] T. Yuan, T. Yang, H. Chen et al., “New insights into oxidative
stress and inflammation during diabetes mellitus-accelerated
atherosclerosis,” Redox Biology, vol. 20, pp. 247–260, 2019.
[13] M. Brownlee, “Biochemistry and molecular cell biology of
diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–
820, 2001.
[14] M. Vrsalovic, “Diabetes and peripheral artery disease: a bad
combination,” The American Journal of Surgery, vol. 216,
no. 1, pp. 182-183, 2018.
9Mediators of Inflammation
[15] I. Baumgartner, L. Norgren, F. G. R. Fowkes et al., “Cardio-
vascular outcomes after lower extremity endovascular or
surgical revascularization: the EUCLID Trial,” Journal of the
American College of Cardiology, vol. 72, no. 14, pp. 1563–
1572, 2018.
[16] T. Mueller, F. Hinterreiter, W. Poelz, M. Haltmayer, and
B. Dieplinger, “The heart matters in diabetes: 10-year out-
comes of peripheral artery disease,” SAGE Open Medicine,
vol. 5, 2017.
[17] F. G. R. Fowkes, D. Rudan, I. Rudan et al., “Comparison of
global estimates of prevalence and risk factors for peripheral
artery disease in 2000 and 2010: a systematic review and
analysis,” The Lancet, vol. 382, no. 9901, pp. 1329–1340, 2013.
[18] M. H. Criqui and V. Aboyans, “Epidemiology of peripheral
artery disease,” Circulation Research, vol. 116, no. 9,
pp. 1509–1526, 2015.
[19] E. B. Jude, S. O. Oyibo, N. Chalmers, and A. J. M. Boulton,
“Peripheral arterial disease in diabetic and nondiabetic
patients: a comparison of severity and outcome,” Diabetes
Care, vol. 24, no. 8, pp. 1433–1437, 2001.
[20] E. J. Boyko, A. D. Seelig, and J. H. Ahroni, “Limb- and
person-level risk factors for lower-limb amputation in the
prospective Seattle Diabetic Foot Study,” Diabetes Care,
vol. 41, no. 4, pp. 891–898, 2018.
[21] A. Flex, E. Gaetani, F. Angelini et al., “Pro-inflammatory
genetic profiles in subjects with peripheral arterial occlusive
disease and critical limb ischemia,” Journal of Internal
Medicine, vol. 262, no. 1, pp. 124–130, 2007.
[22] P. E. Norman, W. A. Davis, D. G. Bruce, and T. M. E. Davis,
“Peripheral arterial disease and risk of cardiac death in type 2
diabetes: the Fremantle Diabetes Study,” Diabetes Care,
vol. 29, no. 3, pp. 575–580, 2006.
[23] K. Mohammedi, M. Woodward, Y. Hirakawa et al., “Presen-
tations of major peripheral arterial disease and risk of major
outcomes in patients with type 2 diabetes: results from the
ADVANCE-ON study,” Cardiovascular Diabetology,
vol. 15, no. 1, p. 129, 2016.
[24] J. A. Dormandy, D. J. Betteridge, G. Schernthaner, V. Pirags,
L. Norgren, and PROactive Investigators, “Impact of periph-
eral arterial disease in patients with diabetes—results from
PROactive (PROactive 11),” Atherosclerosis, vol. 202, no. 1,
pp. 272–281, 2009.
[25] K. Mohammedi, M. Woodward, S. Zoungas et al., “Absence
of peripheral pulses and risk of major vascular outcomes in
patients with type 2 diabetes,” Diabetes Care, vol. 39, no. 12,
pp. 2270–2277, 2016.
[26] M. Nativel, L. Potier, L. Alexandre et al., “Lower extremity
arterial disease in patients with diabetes: a contemporary nar-
rative review,” Cardiovascular Diabetology, vol. 17, no. 1,
p. 138, 2018.
[27] J. L. Sonnenburg and F. Bäckhed, “Diet–microbiota interac-
tions as moderators of human metabolism,” Nature,
vol. 535, no. 7610, pp. 56–64, 2016.
[28] J. Budzyński, J. Wiśniewska, M. Ciecierski, and A. Kędzia,
“Association between bacterial infection and peripheral vas-
cular disease: a review,” International Journal of Angiology,
vol. 25, no. 1, pp. 3–13, 2016.
[29] D. J. Lamb, W. el-Sankary, and G. A. A. Ferns, “Molecular
mimicry in atherosclerosis: a role for heat shock proteins in
immunisation,” Atherosclerosis, vol. 167, no. 2, pp. 177–185,
2003.
[30] R. Sessa, M. D. Pietro, S. Filardo, and O. Turriziani, “Infec-
tious burden and atherosclerosis: a clinical issue,” World
Journal of Clinical Cases, vol. 2, no. 7, pp. 240–249, 2014.
[31] F. Franceschi, G. Niccoli, G. Ferrante et al., “CagA antigen of
Helicobacter pylori and coronary instability: insight from a
clinico-pathological study and a meta-analysis of 4241 cases,”
Atherosclerosis, vol. 202, no. 2, pp. 535–542, 2009.
[32] T. Dietrich, P. Sharma, C. Walter, P. Weston, and J. Beck,
“The epidemiological evidence behind the association
between periodontitis and incident atherosclerotic cardiovas-
cular disease,” Journal of Clinical Periodontology, vol. 40,
Supplement 14, pp. S70–S84, 2013.
[33] U. Ahmed and F. Tanwir, “Association of periodontal
pathogenesis and cardiovascular diseases: a literature review,”
Oral Health and Preventive Dentistry, vol. 13, no. 1, pp. 21–
27, 2015.
[34] A. L. Caúla, R. Lira-Junior, E. M. B. Tinoco, and R. G. Fischer,
“The effect of periodontal therapy on cardiovascular risk
markers: a 6-month randomized clinical trial,” Journal of
Clinical Periodontology, vol. 41, no. 9, pp. 875–882, 2014.
[35] Y. Nagatomo and W. H. W. Tang, “Intersections between
microbiome and heart failure: revisiting the gut hypothesis,”
Journal of Cardiac Failure, vol. 21, no. 12, pp. 973–980, 2015.
[36] R. Karbasi-Afshar, H. Khedmat, and M. Izadi, “Helicobacter
pylori infection and atherosclerosis: a systematic review,”
Acta Medica Iranica, vol. 53, no. 2, pp. 78–88, 2015.
[37] H. Rangé, J. Labreuche, L. Louedec et al., “Periodontal bacte-
ria in human carotid atherothrombosis as a potential trigger
for neutrophil activation,” Atherosclerosis, vol. 236, no. 2,
pp. 448–455, 2014.
[38] A. R. L. Aquino, K. C. Lima, M. S. Paiva, I. N. Rôças, and J. F.
Siqueira Jr., “Molecular survey of atheromatous plaques for
the presence of DNA from periodontal bacterial pathogens,
archaea and fungi,” Journal of Periodontal Research, vol. 46,
no. 3, pp. 303–309, 2011.
[39] E. Figuero, C. Lindahl, M. J. Marín et al., “Quantification of
periodontal pathogens in vascular, blood, and subgingival
samples from patients with peripheral arterial disease or
abdominal aortic aneurysms,” Journal of Periodontology,
vol. 85, no. 9, pp. 1182–1193, 2014.
[40] M. Kowalski, “Helicobacter pylori (H. pylori) infection in cor-
onary artery disease: influence ofH. pylori eradication on cor-
onary artery lumen after percutaneous transluminal coronary
angioplasty. The detection of H. pylori specific DNA in
human coronary atherosclerotic plaque,” Journal of Physiol-
ogy and Pharmacology, vol. 52, no. 1, Supplement 1, pp. 3–
31, 2001.
[41] M. Kowalski, P. C. Konturek, P. Pieniazek et al., “Prevalence
ofHelicobacter pylori infection in coronary artery disease and
effect of its eradication an coronary lumen reduction after
percutations coronaryangioplasty,” Digestive and Liver Dis-
ease, vol. 33, no. 3, pp. 222–229, 2001.
[42] B. Chiu, “Multiple infections in carotid atherosclerotic pla-
ques,” American Heart Journal, vol. 138, no. 5, pp. S534–
S536, 1999.
[43] S. K. Rath, M. Mukherjee, R. Kaushik, S. Sen, and M. Kumar,
“Periodontal pathogens in atheromatous plaque,” Indian
Journal of Pathology and Microbiology, vol. 57, no. 2,
pp. 259–264, 2014.
[44] E. Iriz, M. Y. Cirak, E. D. Engin et al., “Detection of Helico-
bacter pyloriDNA in aortic and left internal mammary artery
10 Mediators of Inflammation
biopsies,” Texas Heart Institute Journal, vol. 35, no. 2,
pp. 130–135, 2008.
[45] A. Vcev, D. Nakić, A. Mrden et al., “Helicobacter pylori infec-
tion and coronary artery disease,” Collegium Antropologicum,
vol. 31, no. 3, pp. 757–760, 2007.
[46] A. Kilic, O. Onguru, H. Tugcu, S. Kilic, C. Guney, and
Y. Bilge, “Detection of cytomegalovirus and Helicobacter
pylori DNA in arterial walls with grade III atherosclerosis
by PCR,” Polish Journal of Microbiology, vol. 55, no. 4,
pp. 333–337, 2006.
[47] R. Vijayvergiya, N. Agarwal, A. Bahl et al., “Association of
Chlamydia pneumoniae and Helicobacter pylori infection
with angiographically demonstrated coronary artery disease,”
International Journal of Cardiology, vol. 107, no. 3, pp. 428-
429, 2006.
[48] M. Kaplan, S. S. Yavuz, B. Cinar et al., “Detection of Chla-
mydia pneumoniae and Helicobacter pylori in atherosclerotic
plaques of carotid artery by polymerase chain reaction,”
International Journal of Infectious Diseases, vol. 10, no. 2,
pp. 116–123, 2006.
[49] A. K. Adiloglu, A. Ocal, R. Can, H. Duver, T. Yavuz, and B. C.
Aridogan, “Detection of Helicobacter pylori and Chlamydia
pneumoniaeDNA in human coronary arteries and evaluation
of the results with serologic evidence of inflammation,” Saudi
Medical Journal, vol. 26, no. 7, pp. 1068–1074, 2005.
[50] D. Skowasch, A. Jabs, R. Andrié et al., “Pathogen burden,
inflammation, proliferation and apoptosis in human in-
stent restenosis. Tissue characteristics compared to primary
atherosclerosis,” Journal of Vascular Research, vol. 41, no. 6,
pp. 525–534, 2004.
[51] J. Danesh, “Coronary heart disease, Helicobacter pylori, den-
tal disease, Chlamydia pneumoniae, and cytomegalovirus:
meta-analyses of prospective studies,” American Heart
Journal, vol. 138, no. 5, pp. S434–S437, 1999.
[52] J. Danesh and R. Peto, “Risk factors for coronary heart disease
and infection with Helicobacter pylori: meta-analysis of 18
studies,” BMJ, vol. 316, no. 7138, pp. 1130–1132, 1998.
[53] T. Celik, A. Iyisoy, and U. C. Yuksel, “Possible pathogenetic
role of Helicobacter pylori infection in cardiac syndrome X,”
International Journal of Cardiology, vol. 142, no. 2, pp. 193-
194, 2010.
[54] J. Budzyński and M. Kłopocka, “Brain-gut axis in the patho-
genesis of Helicobacter pylori infection,” World Journal of
Gastroenterology, vol. 20, no. 18, pp. 5212–5225, 2014.
[55] J. Budzyński, M. Kłopocka, R. Bujak, M. Światkowski,
G. Pulkowski, and W. Sinkiewicz, “Autonomic nervous func-
tion in Helicobacter pylori-infected patients with atypical
chest pain studied by analysis of heart rate variability,” Euro-
pean Journal of Gastroenterology & Hepatology, vol. 16, no. 5,
pp. 451–457, 2004.
[56] D. Grundy, E. D. al–Chaer, Q. Aziz et al., “Fundamentals of
neurogastroenterology: basic science,” Gastroenterology,
vol. 130, no. 5, pp. 1391–1411, 2006.
[57] A. H. Marques, M. N. Silverman, and E. M. Sternberg, “Eval-
uation of stress systems by applying noninvasive methodolo-
gies: measurements of neuroimmune biomarkers in the
sweat, heart rate variability and salivary cortisol,” Neuroim-
munomodulation, vol. 17, no. 3, pp. 205–208, 2010.
[58] J. D. Wood, “Neuropathophysiology of functional gastroin-
testinal disorders,” World Journal of Gastroenterology,
vol. 13, no. 9, pp. 1313–1332, 2007.
[59] J. Budzyński, M. Koziński, M. Kłopocka, J. M. Kubica, and
J. Kubica, “Clinical significance of Helicobacter pylori infec-
tion in patients with acute coronary syndromes: an overview
of current evidence,” Clinical Research in Cardiology,
vol. 103, no. 11, pp. 855–886, 2014.
[60] T. K. Chatterjee, B. J. Aronow,W. S. Tong et al., “Human cor-
onary artery perivascular adipocytes overexpress genes
responsible for regulating vascular morphology, inflamma-
tion, and hemostasis,” Physiological Genomics, vol. 45,
no. 16, pp. 697–709, 2013.
[61] A. Izzotti, P. Durando, F. Ansaldi, F. Gianiorio, and
A. Pulliero, “Interaction between Helicobacter pylori, diet,
and genetic polymorphisms as related to non-cancer
diseases,” Mutation Research/Fundamental and Molecular
Mechanisms of Mutagenesis, vol. 667, no. 1-2, pp. 142–157,
2009.
[62] L. Chang, H. Milton, D. T. Eitzman, and Y. E. Chen, “Para-
doxical roles of perivascular adipose tissue in atherosclerosis
and hypertension,” Circulation Journal, vol. 77, no. 1,
pp. 11–18, 2013.
[63] J. Y. Tano, J. Schleifenbaum, and M. Gollasch, “Perivascular
adipose tissue, potassium channels, and vascular dysfunc-
tion,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 34, no. 9, pp. 1827–1830, 2014.
[64] F. Karlsson, V. Tremaroli, J. Nielsen, and F. Bäckhed, “Asses-
sing the human gut microbiota in metabolic diseases,” Diabe-
tes, vol. 62, no. 10, pp. 3341–3349, 2013.
[65] C. Determann, A. T. Hill, H. Monaghan, and S. C. Fraser,
“Atypical mycobacteria in a superficial femoral artery occlu-
sion,” BMJ Case Reports, vol. 2011, 2011.
[66] M. Rinaldi, C. Perricone, O. D. Ortega-Hernandez,
R. Perricone, and Y. Shoenfeld, “Immune thrombocytopaenic
purpura: an autoimmune cross-link between infections and
vaccines,” Lupus, vol. 23, no. 6, pp. 554–567, 2014.
[67] D. Gilden, M. A. Nagel, R. Mahalingam et al., “Clinical and
molecular aspects of varicella zoster virus infection,” Future
Neurology, vol. 4, no. 1, pp. 103–117, 2009.
[68] K. M. Tuohy, F. Fava, and R. Viola, “‘The way to a man's
heart is through his gut microbiota’ – dietary pro- and
prebiotics for the management of cardiovascular risk,” Pro-
ceedings of the Nutrition Society, vol. 73, no. 2, pp. 172–185,
2014.
[69] F. H. Karlsson, F. Fåk, I. Nookaew et al., “Symptomatic ath-
erosclerosis is associated with an altered gut metagenome,”
Nature Communications, vol. 3, no. 1, p. 1245, 2012.
[70] C. Karlsson, S. Ahrné, G. Molin et al., “Probiotic therapy to
men with incipient arteriosclerosis initiates increased bacte-
rial diversity in colon: a randomized controlled trial,” Athero-
sclerosis, vol. 208, no. 1, pp. 228–233, 2010.
[71] S. A. Goel, L. W. Guo, B. Liu, and K. C. Kent, “Mechanisms of
post-intervention arterial remodelling,” Cardiovascular
Research, vol. 96, no. 3, pp. 363–371, 2012.
[72] K. D. Krueger, A. K. Mitra, M. DelCore, Hunter WJ 3rd, and
D. K. Agrawal, “A comparison of stent-induced stenosis in
coronary and peripheral arteries,” Journal of Clinical Pathol-
ogy, vol. 59, no. 6, pp. 575–579, 2006.
[73] M. Kozinski, A. Krzewina-Kowalska, J. Kubica et al., “Percu-
taneous coronary intervention triggers a systemic inflamma-
tory response in patients treated for in-stent restenosis –
comparison with stable and unstable angina,” Inflammation
Research, vol. 54, no. 5, pp. 187–193, 2005.
11Mediators of Inflammation
[74] J. Kubica, M. Kozinski, A. Krzewina-Kowalska et al., “Com-
bined periprocedural evaluation of CRP and TNF-α enhances
the prediction of clinical restenosis and major adverse cardiac
events in patients undergoing percutaneous coronary inter-
ventions,” International Journal of Molecular Medicine,
vol. 16, no. 1, pp. 173–180, 2005.
[75] M. Q. Le and C. R. Narins, “Mycotic pseudoaneurysm of the
left circumflex coronary artery: a fatal complication following
drug-eluting stent implantation,” Catheterization and Car-
diovascular Interventions, vol. 69, no. 4, pp. 508–512, 2007.
[76] Y. Yan, S. Silvennoinen-Kassinen, M. Leinonen, and
P. Saikku, “Rapamycin can inhibit the development of
Chlamydia pneumoniae, which might partly contribute to
the prevention of in-stent restenosis,” Cardiovascular Drugs
and Therapy, vol. 24, no. 3, pp. 189–195, 2010.
[77] F. Schiele, M. K. Batur, M. F. Seronde et al., “Cytomegalovi-
rus, Chlamydia pneumoniae, and Helicobacter pylori IgG
antibodies and restenosis after stent implantation: an angio-
graphic and intravascular ultrasound study,” Heart, vol. 85,
no. 3, pp. 304–311, 2001.
[78] J. Zhu, A. A. Quyyumi, J. E. Norman et al., “Effects of total
pathogen burden on coronary artery disease risk and C-
reactive protein levels,” The American Journal of Cardiology,
vol. 85, no. 2, pp. 140–146, 2000.
[79] M. H. Criqui, R. D. Langer, A. Fronek et al., “Mortality over a
period of 10 years in patients with peripheral arterial disease,”
The New England Journal of Medicine, vol. 326, no. 6,
pp. 381–386, 1992.
[80] H. D. Danenberg, F. G. P. Welt, M.Walker III, P. Seifert, G. S.
Toegel, and E. R. Edelman, “Systemic inflammation induced
by lipopolysaccharide increases neointimal formation after
balloon and stent injury in rabbits,” Circulation, vol. 105,
no. 24, pp. 2917–2922, 2002.
[81] A. C. Newby and A. B. Zaltsman, “Molecular mechanisms in
intimal hyperplasia,” The Journal of Pathology, vol. 190, no. 3,
pp. 300–309, 2000.
[82] N. Ohashi, A. Matsumori, Y. Furukawa et al., “Role of p38
mitogen-activated protein kinase in neointimal hyperplasia
after vascular injury,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 20, no. 12, pp. 2521–2526, 2000.
[83] C. G. Pearce, S. F. Najjar, M. R. Kapadia et al., “Beneficial
effect of a short-acting NO donor for the prevention of
neointimal hyperplasia,” Free Radical Biology & Medicine,
vol. 44, no. 1, pp. 73–81, 2008.
[84] C. Y. Miao and Z. Y. Li, “The role of perivascular adipose
tissue in vascular smooth muscle cell growth,” British Journal
of Pharmacology, vol. 165, no. 3, pp. 643–658, 2012.
[85] B. F. Chen, X. Xu, Y. Deng et al., “Relationship between
Helicobacter pylori infection and serum interleukin-18 in
patients with carotid atherosclerosis,” Helicobacter, vol. 18,
no. 2, pp. 124–128, 2013.
[86] J. Chen, M. Zhu, G. Ma, Z. Zhao, and Z. Sun, “Chlamydia
pneumoniae infection and cerebrovascular disease: a system-
atic review andmeta-analysis,” BMCNeurology, vol. 13, no. 1,
p. 183, 2013.
[87] C. A. Thaiss, N. Zmora, M. Levy, and E. Elinav, “The micro-
biome and innate immunity,” Nature, vol. 535, no. 7610,
pp. 65–74, 2016.
[88] F. Biscetti, A. Flex, S. Alivernini, B. Tolusso, E. Gremese, and
G. Ferraccioli, “The role of high-mobility group box-1 and its
crosstalk with microbiome in rheumatoid arthritis,”
Mediators of Inflammation, vol. 2017, Article ID 5230374,
11 pages, 2017.
[89] J. Qin, R. Li, J. Raes et al., “A human gut microbial gene
catalogue established by metagenomic sequencing,” Nature,
vol. 464, no. 7285, pp. 59–65, 2010.
[90] S. Tamburini, N. Shen, H. C. Wu, and J. C. Clemente, “The
microbiome in early life: implications for health outcomes,”
Nature Medicine, vol. 22, no. 7, pp. 713–722, 2016.
[91] R. N. Carmody, G. K. Gerber, J. M. Luevano Jr. et al.,
“Diet dominates host genotype in shaping the murine gut
microbiota,” Cell Host & Microbe, vol. 17, no. 1, pp. 72–84,
2015.
[92] R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Micro-
bial ecology: human gut microbes associated with obesity,”
Nature, vol. 444, no. 7122, pp. 1022-1023, 2006.
[93] P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R.
Mardis, and J. I. Gordon, “An obesity-associated gut micro-
biome with increased capacity for energy harvest,” Nature,
vol. 444, no. 7122, pp. 1027–1031, 2006.
[94] N. Larsen, F. K. Vogensen, F. W. J. van den Berg et al., “Gut
microbiota in human adults with type 2 diabetes differs from
non-diabetic adults,” PLoS One, vol. 5, no. 2, article e9085,
2010.
[95] P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotox-
emia initiates obesity and insulin resistance,” Diabetes,
vol. 56, no. 7, pp. 1761–1772, 2007.
[96] S. J. Creely, P. G. McTernan, C. M. Kusminski et al., “Lipo-
polysaccharide activates an innate immune system response
in human adipose tissue in obesity and type 2 diabetes,”
American Journal of Physiology-Endocrinology and Metabo-
lism, vol. 292, no. 3, pp. E740–E747, 2007.
[97] R. Caesar, C. S. Reigstad, H. K. Bäckhed et al., “Gut-derived
lipopolysaccharide augments adipose macrophage accumula-
tion but is not essential for impaired glucose or insulin tol-
erance in mice,” Gut, vol. 61, no. 12, pp. 1701–1707, 2012.
[98] J. Qin, Y. Li, Z. Cai et al., “A metagenome-wide association
study of gut microbiota in type 2 diabetes,” Nature,
vol. 490, no. 7418, pp. 55–60, 2012.
[99] F. H. Karlsson, V. Tremaroli, I. Nookaew et al., “Gut
metagenome in European women with normal, impaired
and diabetic glucose control,” Nature, vol. 498, no. 7452,
pp. 99–103, 2013.
[100] R. Wall, R. P. Ross, C. A. Ryan et al., “Role of gut microbiota
in early infant development,” Clinical Medicine Insights:
Pediatrics, vol. 3, pp. 45–54, 2009.
[101] T. Yatsunenko, F. E. Rey, M. J. Manary et al., “Human gut
microbiome viewed across age and geography,” Nature,
vol. 486, no. 7402, pp. 222–227, 2012.
[102] A. R. Moschen, V. Wieser, and H. Tilg, “Dietary factors:
major regulators of the gut’s microbiota,” Gut and Liver,
vol. 6, no. 4, pp. 411–416, 2012.
[103] A. L. Kau, P. P. Ahern, N.W. Griffin, A. L. Goodman, and J. I.
Gordon, “Human nutrition, the gut microbiome and the
immune system,” Nature, vol. 474, no. 7351, pp. 327–336,
2011.
[104] X. Zhang, D. Shen, Z. Fang et al., “Human gut microbiota
changes reveal the progression of glucose intolerance,” PLoS
One, vol. 8, no. 8, article e71108, 2013.
[105] H. Tilg and A. R. Moschen, “Microbiota and diabetes: an
evolving relationship,” Gut, vol. 63, no. 9, pp. 1513–1521,
2014.
12 Mediators of Inflammation
[106] N. Arpaia, C. Campbell, X. Fan et al., “Metabolites pro-
duced by commensal bacteria promote peripheral regulatory
T-cell generation,” Nature, vol. 504, no. 7480, pp. 451–455,
2013.
[107] A. Trompette, E. S. Gollwitzer, K. Yadava et al., “Gut micro-
biota metabolism of dietary fiber influences allergic airway
disease and hematopoiesis,” Nature Medicine, vol. 20, no. 2,
pp. 159–166, 2014.
[108] M. Vijay-Kumar, J. D. Aitken, F. A. Carvalho et al., “Meta-
bolic syndrome and altered gut microbiota in mice lacking
Toll-like receptor 5,” Science, vol. 328, no. 5975, pp. 228–
231, 2010.
[109] E. A. Operskalski and A. Kovacs, “HIV/HCV co-infection:
pathogenesis, clinical complications, treatment, and new
therapeutic technologies,” Current HIV/AIDS Reports,
vol. 8, no. 1, pp. 12–22, 2011.
[110] C. M. Ardila, M. Olarte-Sossa, and A. A. Ariza-Garcés,
“Association between the presence of Treponema denticola
and reduced levels of antiatherogenic high density lipopro-
tein in periodontitis,” Quintessence International, vol. 46,
no. 3, pp. 207–215, 2015.
[111] T. Kurita-Ochiai and M. Yamamoto, “Periodontal pathogens
and atherosclerosis: implications of inflammation and oxida-
tive modification of LDL,” BioMed Research International,
vol. 2014, Article ID 595981, 7 pages, 2014.
[112] B. Huang, Y. Chen, Q. Xie et al., “CagA-positive Helicobacter
pylori strains enhanced coronary atherosclerosis by increas-
ing serum OxLDL and HsCRP in patients with coronary
heart disease,” Digestive Diseases and Sciences, vol. 56, no. 1,
pp. 109–114, 2011.
[113] P. Libby, “Inflammation in atherosclerosis,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2045–
2051, 2012.
[114] M. Krintus, M. Kozinski, A. Stefanska et al., “Value of C-
reactive protein as a risk factor for acute coronary syndrome:
a comparison with apolipoprotein concentrations and lipid
profile,” Mediators of Inflammation, vol. 2012, Article ID
419804, 10 pages, 2012.
[115] M. E. Rosenfeld and L. A. Campbell, “Pathogens and athero-
sclerosis: update on the potential contribution of multiple
infectious organisms to the pathogenesis of atherosclerosis,”
Thrombosis and Haemostasis, vol. 106, no. 5, pp. 858–867,
2011.
[116] M. F. Byrne, S. W. Kerrigan, P. A. Corcoran et al., “Helicobac-
ter pylori binds von Willebrand factor and interacts with
GPIb to induce platelet aggregation,” Gastroenterology,
vol. 124, no. 7, pp. 1846–1854, 2003.
[117] K. Satoh, T. Hirayama, K. Takano et al., “VacA, the vacuolat-
ing cytotoxin ofHelicobacter pylori, binds to multimerin 1 on
human platelets,” Thrombosis Journal, vol. 11, no. 1, p. 23,
2013.
[118] Y. J. Gao, “Dual modulation of vascular function by
perivascular adipose tissue and its potential correlation
with adiposity/lipoatrophy-related vascular dysfunction,”
Current Pharmaceutical Design, vol. 13, no. 21, pp. 2185–
2192, 2007.
[119] R. P. Tapashetti, S. Guvva, S. R. Patil, S. Sharma, and H. M.
Pushpalatha, “C-reactive protein as predict of increased
carotid intima media thickness in patients with chronic
periodontitis,” Journal of International Oral Health, vol. 6,
no. 4, pp. 47–52, 2014.
[120] T. Kosaka, Y. Kokubo, T. Ono et al., “Salivary inflammatory
cytokines may be novel markers of carotid atherosclerosis
in a Japanese general population: the Suita study,” Atheroscle-
rosis, vol. 237, no. 1, pp. 123–128, 2014.
[121] Y. W. Chen, M. Umeda, T. Nagasawa et al., “Periodontitis
may increase the risk of peripheral arterial disease,” European
Journal of Vascular and Endovascular Surgery, vol. 35, no. 2,
pp. 153–158, 2008.
[122] M. Serino, V. Blasco-Baque, S. Nicolas, and R. Burcelin, “Far
from the eyes, close to the heart: dysbiosis of gut microbiota
and cardiovascular consequences,” Current Cardiology
Reports, vol. 16, no. 11, p. 540, 2014.
[123] A. Fukasawa, T. Kurita-Ochiai, T. Hashizume, R. Kobayashi,
Y. Akimoto, and M. Yamamoto, “Porphyromonas gingivalis
accelerates atherosclerosis in C57BL/6 mice fed a high-fat
diet,” Immunopharmacology and Immunotoxicology, vol. 34,
no. 3, pp. 470–476, 2012.
[124] M. Gabrielli, A. Santoliquido, F. Cremonini et al., “CagA-pos-
itive cytotoxicH. pylori strains as a link between plaque insta-
bility and atherosclerotic stroke,” European Heart Journal,
vol. 25, no. 1, pp. 64–68, 2004.
[125] D. L. Johnson, C. B. Stone, D. C. Bulir, B. K. Coombes, and
J. B. Mahony, “A novel inhibitor of Chlamydophila pneumo-
niae protein kinase D (PknD) inhibits phosphorylation of
CdsD and suppresses bacterial replication,” BMC Microbiol-
ogy, vol. 9, no. 1, p. 218, 2009.
[126] Y. W. Han, W. Houcken, B. G. Loos, H. A. Schenkein, and
M. Tezal, “Periodontal disease, atherosclerosis, adverse
pregnancy outcomes, and head-and-neck cancer,” Advances
in Dental Research, vol. 26, no. 1, pp. 47–55, 2014.
[127] M. Mayr, S. Kiechl, M. A. Mendall, J. Willeit, G. Wick, and
Q. Xu, “Increased risk of atherosclerosis is confined to
CagA-positive Helicobacter pylori strains: prospective results
from the Bruneck study,” Stroke, vol. 34, no. 3, pp. 610–615,
2003.
[128] M. Diomedi, A. Pietroiusti, M. Silvestrini et al., “CagA-posi-
tive Helicobacter pylori strains may influence the natural
history of atherosclerotic stroke,” Neurology, vol. 63, no. 5,
pp. 800–804, 2004.
[129] Z.Wang, E. Klipfell, B. J. Bennett et al., “Gut flora metabolism
of phosphatidylcholine promotes cardiovascular disease,”
Nature, vol. 472, no. 7341, pp. 57–63, 2011.
[130] M. Lee-Rueckert, F. Blanco-Vaca, P. T. Kovanen, and J. C.
Escola-Gil, “The role of the gut in reverse cholesterol trans-
port – focus on the enterocyte,” Progress in Lipid Research,
vol. 52, no. 3, pp. 317–328, 2013.
[131] J. Loscalzo, “Lipid metabolism by gut microbes and athero-
sclerosis,” Circulation Research, vol. 109, no. 2, pp. 127–129,
2011.
[132] J. Hulthe and B. Fagerberg, “Circulating oxidized LDL is
associated with increased levels of cell-adhesion molecules
in clinically healthy 58-year old men (AIR study),” Medi-
cal Science Monitor, vol. 8, no. 3, pp. CR148–CR152,
2002.
[133] D. Li, L. Liu, H. Chen, T. Sawamura, and J. L. Mehta, “LOX-1,
an oxidized LDL endothelial receptor, induces CD40/CD40L
signaling in human coronary artery endothelial cells,” Arte-
riosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5,
pp. 816–821, 2003.
[134] J. Suzuki, N. Aoyama, M. Aoki et al., “High incidence of peri-
odontitis in Japanese patients with abdominal aortic
13Mediators of Inflammation
aneurysm,” International Heart Journal, vol. 55, no. 3,
pp. 268–270, 2014.
[135] E. Leivadaros, U. Velden, S. Bizzarro et al., “A pilot study
into measurements of markers of atherosclerosis in peri-
odontitis,” Journal of Periodontology, vol. 76, no. 1, pp. 121–
128, 2005.
[136] K. Buhlin, M. Hultin, O. Norderyd et al., “Risk factors for ath-
erosclerosis in cases with severe periodontitis,” Journal of
Clinical Periodontology, vol. 36, no. 7, pp. 541–549, 2009.
[137] Y. Higashi, C. Goto, T. Hidaka et al., “Oral infection-
inflammatory pathway, periodontitis, is a risk factor for
endothelial dysfunction in patients with coronary artery dis-
ease,” Atherosclerosis, vol. 206, no. 2, pp. 604–610, 2009.
[138] S. Fedele, W. Sabbah, N. Donos, S. Porter, and F. D'Aiuto,
“Common oral mucosal diseases, systemic inflammation,
and cardiovascular diseases in a large cross-sectional US sur-
vey,” American Heart Journal, vol. 161, no. 2, pp. 344–350,
2011.
[139] J. B. Bartruff, R. A. Yukna, and D. L. Layman, “Outer mem-
brane vesicles from Porphyromonas gingivalis affect the
growth and function of cultured human gingival fibroblasts
and umbilical vein endothelial cells,” Journal of Periodontol-
ogy, vol. 76, no. 6, pp. 972–979, 2005.
[140] R. E. Fitzpatrick, L. C. Wijeyewickrema, and R. N. Pike, “The
gingipains: scissors and glue of the periodontal pathogen,
Porphyromonas gingivalis,” Future Microbiology, vol. 4,
no. 4, pp. 471–487, 2009.
[141] E. Blessing, L. A. Campbell, M. E. Rosenfeld, N. Chough, and
C. C. Kuo, “Chlamydia pneumoniae infection accelerates
hyperlipidemia induced atherosclerotic lesion development
in C57BL/6J mice,” Atherosclerosis, vol. 158, no. 1, pp. 13–
17, 2001.
[142] K. J. Ho, L. Xiong, N. J. Hubert et al., “Vancomycin treatment
and butyrate supplementation modulate gut microbe compo-
sition and severity of neointimal hyperplasia after arterial
injury,” Physiological Reports, vol. 3, no. 12, article e12627,
2015.
[143] H. Rud Andersen, M. Mæng, M. Thorwest, and E. Falk,
“Remodeling rather than neointimal formation explains
luminal narrowing after deep vessel wall injury: insights from
a porcine coronary (re)stenosis model,” Circulation, vol. 93,
no. 9, pp. 1716–1724, 1996.
[144] R. Hoffmann, G. S. Mintz, G. R. Dussaillant et al., “Patterns
and mechanisms of in-stent restenosis. A serial intravascular
ultrasound study,” Circulation, vol. 94, no. 6, pp. 1247–1254,
1996.
[145] C. A. Cason, K. T. Dolan, G. Sharma et al., “Plasma
microbiome-modulated indole- and phenyl-derived metabo-
lites associate with advanced atherosclerosis and postopera-
tive outcomes,” Journal of Vascular Surgery, vol. 68, no. 5,
pp. 1552–1562.e7, 2018.
[146] T. W. Stone and L. G. Darlington, “Endogenous kynurenines
as targets for drug discovery and development,” Nature
Reviews Drug Discovery, vol. 1, no. 8, pp. 609–620, 2002.
[147] N. Yoshida, T. Yamashita, and K. I. Hirata, “Gut microbiome
and cardiovascular diseases,” Diseases, vol. 6, no. 3, p. 56,
2018.
[148] K. Yang, C. du, X. Wang et al., “Indoxyl sulfate induces plate-
let hyperactivity and contributes to chronic kidney disease–
associated thrombosis in mice,” Blood, vol. 129, no. 19,
pp. 2667–2679, 2017.
[149] G. Clarke, S. Grenham, P. Scully et al., “The microbiome-gut-
brain axis during early life regulates the hippocampal seroto-
nergic system in a sex-dependent manner,”Molecular Psychi-
atry, vol. 18, no. 6, pp. 666–673, 2013.
[150] S. El Aidy, W. Kunze, J. Bienenstock, and M. Kleerebezem,
“The microbiota and the gut-brain axis: insights from the
temporal and spatial mucosal alterations during colonisation
of the germfree mouse intestine,” Beneficial Microbes, vol. 3,
no. 4, pp. 251–259, 2012.
[151] A. Adijiang, S. Goto, S. Uramoto, F. Nishijima, and T. Niwa,
“Indoxyl sulphate promotes aortic calcification with expres-
sion of osteoblast-specific proteins in hypertensive rats,”
Nephrology Dialysis Transplantation, vol. 23, no. 6,
pp. 1892–1901, 2008.
[152] M. H. Janeiro, M. J. Ramírez, F. I. Milagro, J. A. Martínez, and
M. Solas, “Implication of trimethylamine N-oxide (tmao) in
disease: potential biomarker or new therapeutic target,”
Nutrients, vol. 10, no. 10, p. 1398, 2018.
[153] V. Senthong, Z. Wang, Y. Fan, Y. Wu, S. L. Hazen, andW. H.
W. Tang, “Trimethylamine N-oxide and mortality risk in
patients with peripheral artery disease,” Journal of the
American Heart Association, vol. 5, no. 10, 2016.
[154] R. A. Koeth, Z. Wang, B. S. Levison et al., “Intestinal microbi-
ota metabolism of L-carnitine, a nutrient in red meat, pro-
motes atherosclerosis,” Nature Medicine, vol. 19, no. 5,
pp. 576–585, 2013.
[155] W. H. W. Tang, Z. Wang, B. S. Levison et al., “Intestinal
microbial metabolism of phosphatidylcholine and cardiovas-
cular risk,” The New England Journal of Medicine, vol. 368,
no. 17, pp. 1575–1584, 2013.
[156] Z. Wang, W. H. W. Tang, J. A. Buffa et al., “Prognostic value
of choline and betaine depends on intestinal microbiota-
generated metabolite trimethylamine-N-oxide,” European
Heart Journal, vol. 35, no. 14, pp. 904–910, 2014.
[157] W. H. W. Tang, Z. Wang, K. Shrestha et al., “Intestinal
microbiota-dependent phosphatidylcholine metabolites, dia-
stolic dysfunction, and adverse clinical outcomes in chronic
systolic heart failure,” Journal of Cardiac Failure, vol. 21,
no. 2, pp. 91–96, 2015.
[158] D. M. Shih, Z. Wang, R. Lee et al., “Flavin containing mono-
oxygenase 3 exerts broad effects on glucose and lipid metab-
olism and atherosclerosis,” Journal of Lipid Research, vol. 56,
no. 1, pp. 22–37, 2015.
[159] J. Miao, A. V. Ling, P. V. Manthena et al., “Flavin-containing
monooxygenase 3 as a potential player in diabetes-associated
atherosclerosis,” Nature Communications, vol. 6, no. 1,
p. 6498, 2015.
[160] V. Senthong, X. S. Li, T. Hudec et al., “Plasma trimethylamine
N-oxide, a gut microbe–generated phosphatidylcholine
metabolite, is associated with atherosclerotic burden,” Jour-
nal of the American College of Cardiology, vol. 67, no. 22,
pp. 2620–2628, 2016.
[161] V. Senthong, Z. Wang, X. S. Li et al., “Intestinal microbiota-
generated metabolite trimethylamine-N-oxide and 5-year
mortality risk in stable coronary artery disease: the contribu-
tory role of intestinal microbiota in a COURAGE-like patient
cohort,” Journal of the American Heart Association, vol. 5,
no. 6, 2016.
[162] K. Chen, X. Zheng, M. Feng, D. Li, and H. Zhang, “Gut
microbiota-dependent metabolite trimethylamine N-oxide
contributes to cardiac dysfunction in Western diet-induced
obese mice,” Frontiers in Physiology, vol. 8, p. 139, 2017.
14 Mediators of Inflammation
[163] N. E. Boutagy, A. P. Neilson, K. L. Osterberg et al., “Probiotic
supplementation and trimethylamine-N-oxide production
following a high-fat diet,” Obesity, vol. 23, no. 12, pp. 2357–
2363, 2015.
[164] N. E. Boutagy, A. P. Neilson, K. L. Osterberg et al., “Short-
term high-fat diet increases postprandial trimethylamine-N-
oxide in humans,” Nutrition Research, vol. 35, no. 10,
pp. 858–864, 2015.
[165] X. Gao, J. Xu, C. Jiang et al., “Fish oil ameliorates trimethyla-
mine N-oxide-exacerbated glucose intolerance in high-fat
diet-fed mice,” Food & Function, vol. 6, no. 4, pp. 1117–
1125, 2015.
[166] D. Y. Hui, “Intestinal phospholipid and lysophospholipid
metabolism in cardiometabolic disease,” Current Opinion in
Lipidology, vol. 27, no. 5, pp. 507–512, 2016.
[167] G. Sun, Z. Yin, N. Liu et al., “Gut microbial metabolite
TMAO contributes to renal dysfunction in a mouse model
of diet-induced obesity,” Biochemical and Biophysical
Research Communications, vol. 493, no. 2, pp. 964–970, 2017.
[168] M. Wang, F. Wang, Y. Wang, X. Ma, M. Zhao, and C. Zhao,
“Metabonomics study of the therapeutic mechanism of
Gynostemma pentaphyllum and atorvastatin for hyperlipid-
emia in rats,” PLoS One, vol. 8, no. 11, article e78731, 2013.
[169] D. Mafra, N. A. Borges, L. F. M. F. Cardozo et al., “Red meat
intake in chronic kidney disease patients: two sides of the
coin,” Nutrition, vol. 46, pp. 26–32, 2018.
[170] S. H. Zeisel and M. Warrier, “Trimethylamine N-oxide, the
microbiome, and heart and kidney disease,” Annual Review
of Nutrition, vol. 37, no. 1, pp. 157–181, 2017.
[171] Z. Wang, A. B. Roberts, J. A. Buffa et al., “Non-lethal inhibi-
tion of gut microbial trimethylamine production for the
treatment of atherosclerosis,” Cell, vol. 163, no. 7, pp. 1585–
1595, 2015.
[172] M. Warrier, D. M. Shih, A. C. Burrows et al., “The TMAO-
generating enzyme flavin monooxygenase 3 is a central regu-
lator of cholesterol balance,” Cell Reports, vol. 10, no. 3,
pp. 326–338, 2015.
[173] M. al-Obaide, R. Singh, P. Datta et al., “Gut microbiota-
dependent trimethylamine-N-oxide and serum biomarkers
in patients with T2DM and advanced CKD,” Journal of
Clinical Medicine, vol. 6, no. 9, p. 86, 2017.
[174] A. Nowiński and M. Ufnal, “Trimethylamine N-oxide: a
harmful, protective or diagnostic marker in lifestyle dis-
eases?,” Nutrition, vol. 46, pp. 7–12, 2018.
[175] M. Konop, M. Radkowski, M. Grochowska, K. Perlejewski,
E. Samborowska, and M. Ufnal, “Enalapril decreases rat
plasma concentration of TMAO, a gut bacteria-derived
cardiovascular marker,” Biomarkers, vol. 23, no. 4, pp. 380–
385, 2018.
[176] M. Lever, P. M. George, S. Slow et al., “Betaine and trimethy-
lamine-N-oxide as predictors of cardiovascular outcomes
show different patterns in diabetes mellitus: an observational
study,” PLoS One, vol. 9, no. 12, article e114969, 2014.
[177] A. Mente, K. Chalcraft, H. Ak et al., “The relationship
between trimethylamine-N-oxide and prevalent cardiovascu-
lar disease in a multiethnic population living in Canada,”
Canadian Journal of Cardiology, vol. 31, no. 9, pp. 1189–
1194, 2015.
[178] M. Trøseid, T. Ueland, J. R. Hov et al., “Microbiota-depen-
dent metabolite trimethylamine-N-oxide is associated with
disease severity and survival of patients with chronic heart
failure,” Journal of Internal Medicine, vol. 277, no. 6,
pp. 717–726, 2015.
[179] H. L. Weiner, “Induction of oral tolerance to the acetylcho-
line receptor for treatment of myasthenia gravis,” Journal of
Clinical Investigation, vol. 104, no. 12, pp. 1667-1668, 1999.
[180] C. J. Calder, L. B. Nicholson, and A. D. Dick, “Mechanisms
for inducing nasal mucosal tolerance in experimental auto-
immune uveoretinitis,” Methods, vol. 38, no. 2, pp. 69–76,
2006.
[181] S. Wolfram, “Effects of green tea and EGCG on cardiovascu-
lar and metabolic health,” Journal of the American College of
Nutrition, vol. 26, no. 4, pp. 373S–388S, 2007.
[182] Q. Feng, T. Kumagai, Y. Torii, Y. Nakamura, T. Osawa, and
K. Uchida, “Anticarcinogenic antioxidants as inhibitors
against intracellular oxidative stress,” Free Radical Research,
vol. 35, no. 6, pp. 779–788, 2001.
[183] G. L. Tipoe, T. M. Leung, M. W. Hung, and M. L. Fung,
“Green tea polyphenols as an anti-oxidant and anti-
inflammatory agent for cardiovascular protection,” Cardio-
vascular & Hematological Disorders-Drug Targets, vol. 7,
no. 2, pp. 135–144, 2007.
[184] Y. Cao and R. Cao, “Angiogenesis inhibited by drinking tea,”
Nature, vol. 398, no. 6726, p. 381, 1999.
[185] Y. Cai, T. Kurita-Ochiai, T. Hashizume, and M. Yamamoto,
“Green tea epigallocatechin-3-gallate attenuates Porphyro-
monas gingivalis -induced atherosclerosis,” Pathogens and
Disease, vol. 67, no. 1, pp. 76–83, 2013.
[186] A. Vrieze, E. van Nood, F. Holleman et al., “Transfer of
intestinal microbiota from lean donors increases insulin
sensitivity in individuals with metabolic syndrome,” Gas-
troenterology, vol. 143, no. 4, pp. 913–916.e7, 2012.
[187] P. Hernández-Alonso, D. Cañueto, S. Giardina et al., “Effect
of pistachio consumption on the modulation of urinary gut
microbiota-related metabolites in prediabetic subjects,” The
Journal of Nutritional Biochemistry, vol. 45, pp. 48–53, 2017.
[188] C. Zhang, A. Yin, H. Li et al., “Dietary modulation of gut
microbiota contributes to alleviation of both genetic and sim-
ple obesity in children,” EBioMedicine, vol. 2, no. 8, pp. 968–
984, 2015.
[189] F.-P. J. Martin, Y. Wang, N. Sprenger et al., “Probiotic mod-
ulation of symbiotic gut microbial–host metabolic interac-
tions in a humanized microbiome mouse model,” Molecular
Systems Biology, vol. 4, p. 157, 2008.
[190] R. Spector, “New insight into the dietary cause of atheroscle-
rosis: implications for pharmacology,” Journal of Pharmacol-
ogy and Experimental Therapeutics, vol. 358, no. 1, pp. 103–
108, 2016.
[191] B. Sun, X. Wang, R. Cao et al., “NMR-based metabonomics
study on the effect of Gancao in the attenuation of toxicity
in rats induced by Fuzi,” Journal of Ethnopharmacology,
vol. 193, pp. 617–626, 2016.
[192] V. Lam, J. Su, A. Hsu, G. J. Gross, N. H. Salzman, and J. E.
Baker, “Intestinal microbial metabolites are linked to severity
of myocardial infarction in rats,” PLoS One, vol. 11, no. 8,
article e0160840, 2016.
[193] J. K. Nicholson, E. Holmes, and I. D. Wilson, “Gut microor-
ganisms, mammalian metabolism and personalized health
care,” Nature Reviews Microbiology, vol. 3, no. 5, pp. 431–
438, 2005.
[194] W. R. Wikoff, A. T. Anfora, J. Liu et al., “Metabolomics anal-
ysis reveals large effects of gut microflora on mammalian
15Mediators of Inflammation
blood metabolites,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 106, no. 10,
pp. 3698–3703, 2009.
[195] N. I. Fedotcheva, R. E. Kazakov, M. N. Kondrashova, and
N. V. Beloborodova, “Toxic effects of microbial phenolic
acids on the functions of mitochondria,” Toxicology Letters,
vol. 180, no. 3, pp. 182–188, 2008.
[196] Y. T. Xuan, Y. Guo, H. Han, Y. Zhu, and R. Bolli, “An
essential role of the JAK-STAT pathway in ischemic pre-
conditioning,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 98, no. 16,
pp. 9050–9055, 2001.
[197] J. H. Hanke, J. P. Gardner, R. L. Dow et al., “Discovery of a
novel, potent, and Src family-selective tyrosine kinase inhib-
itor. Study of Lck- and FynT-dependent T cell activation,”
Journal of Biological Chemistry, vol. 271, no. 2, pp. 695–701,
1996.
[198] Y. Liu, A. Bishop, L. Witucki et al., “Structural basis for
selective inhibition of Src family kinases by PP1,” Chemistry
& Biology, vol. 6, no. 9, pp. 671–678, 1999.
[199] H. Ungefroren, S. Sebens, S. Groth, F. Gieseler, and
F. Fändrich, “The Src family kinase inhibitors PP2 and PP1
block TGF-beta1-mediated cellular responses by direct and
differential inhibition of type I and type II TGF-beta
receptors,” Current Cancer Drug Targets, vol. 11, no. 4,
pp. 524–535, 2011.
[200] P. Louis and H. J. Flint, “Diversity, metabolism and microbial
ecology of butyrate-producing bacteria from the human large
intestine,” FEMSMicrobiology Letters, vol. 294, no. 1, pp. 1–8,
2009.
[201] P. Louis, P. Young, G. Holtrop, and H. J. Flint, “Diversity of
human colonic butyrate-producing bacteria revealed by anal-
ysis of the butyryl-CoA:acetate CoA-transferase gene,” Envi-
ronmental Microbiology, vol. 12, no. 2, pp. 304–314, 2010.
[202] H. Rajkumar, N. Mahmood, M. Kumar, S. R. Varikuti, H. R.
Challa, and S. P. Myakala, “Effect of probiotic (VSL#3) and
omega-3 on lipid profile, insulin sensitivity, inflammatory
markers, and gut colonization in overweight adults: a ran-
domized, controlled trial,” Mediators of Inflammation,
vol. 2014, Article ID 348959, 8 pages, 2014.
[203] M. L. Jones, C. J. Martoni, M. Parent, and S. Prakash, “Cho-
lesterol-lowering efficacy of a microencapsulated bile salt
hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt
formulation in hypercholesterolaemic adults,” British Journal
of Nutrition, vol. 107, no. 10, pp. 1505–1513, 2012.
[204] M. Kumar, S. Rakesh, R. Nagpal et al., “Probiotic Lactobacil-
lus rhamnosus GG and Aloe vera gel improve lipid profiles in
hypercholesterolemic rats,” Nutrition, vol. 29, no. 3, pp. 574–
579, 2013.
[205] C. C. Tai and S. T. Ding, “N-3 polyunsaturated fatty acids
regulate lipid metabolism through several inflammation
mediators: mechanisms and implications for obesity preven-
tion,” The Journal of Nutritional Biochemistry, vol. 21, no. 5,
pp. 357–363, 2010.
[206] M. Root, S. R. Collier, K. A. Zwetsloot, K. L. West, and M. C.
McGinn, “A randomized trial of fish oil omega-3 fatty acids
on arterial health, inflammation, and metabolic syndrome
in a young healthy population,” Nutrition Journal, vol. 12,
no. 1, 2013.
[207] Y. Adkins and D. S. Kelley, “Mechanisms underlying the car-
dioprotective effects of omega-3 polyunsaturated fatty acids,”
The Journal of Nutritional Biochemistry, vol. 21, no. 9,
pp. 781–792, 2010.
[208] K. Hatakka, M. Mutanen, R. Holma, M. Saxelin, and
R. Korpela, “Lactobacillus rhamnosus LC705 together with
Propionibacterium freudenreichii ssp shermanii JS adminis-
tered in capsules is ineffective in lowering serum lipids,” Jour-
nal of the American College of Nutrition, vol. 27, no. 4,
pp. 441–447, 2008.
[209] L. A. Simons, S. G. Amansec, and P. Conway, “Effect of
Lactobacillus fermentum on serum lipids in subjects with
elevated serum cholesterol,” Nutrition, Metabolism and
Cardiovascular Diseases, vol. 16, no. 8, pp. 531–535, 2006.
[210] S. J. Lewis and S. Burmeister, “A double-blind placebo-
controlled study of the effects of Lactobacillus acidophilus
on plasma lipids,” European Journal of Clinical Nutrition,
vol. 59, no. 6, pp. 776–780, 2005.
[211] H. Rajkumar, M. Kumar, N. Das, S. N. Kumar, H. R. Challa,
and R. Nagpal, “Effect of probiotic Lactobacillus salivarius
UBL S22 and prebiotic fructo-oligosaccharide on serum
lipids, inflammatory markers, insulin sensitivity, and gut bac-
teria in healthy young volunteers: a randomized controlled
single-blind pilot study,” Journal of Cardiovascular Pharma-
cology and Therapeutics, vol. 20, no. 3, pp. 289–298, 2015.
16 Mediators of Inflammation
